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The frequency of DRD2 rs1076560 
and OPRM1 rs1799971 in substance use disorder 
patients from the United Arab Emirates
Hiba Alblooshi1,2, Gary Hulse2,3, Wael Osman4, Ahmed El Kashef5, Mansour Shawky5, Hamad Al Ghaferi5, 
Habiba Al Safar4,6 and Guan K. Tay2,3,4,6* 
Abstract 
Background: Dopaminergic and opioid systems are involved in mediating drug reward and reinforcement of various 
types of substances including psychoactive compounds. Genes of both systems have been candidate for investiga-
tion for associations with substance use disorder (SUD) in various populations. This study is the first study to deter-
mine the allele frequency and the genetic association of the DRD2 rs1076560 SNP and OPRM1 rs1799971 SNP variants 
in clinically diagnosed patients with SUD from the United Arab Emirates (UAE).
Methods: A cross-sectional case–control cohort that consisted of 512 male subjects was studied. Two hundred and 
fifty patients with SUD receiving treatment at the UAE National Rehabilitation Center were compared to 262 controls 
with no prior history of mental health and SUD. DNA from each subject was extracted and genotyped using the 
 TaqMan® SNP genotyping assay.
Results: There were no significant associations observed for DRD2 rs1076560 SNP, OPRM1 rs1799971 SNP, and com-
bined genotypes of both SNPs in the SUD group.
Conclusion: Further research is required with refinements to the criteria of the clinical phenotypes. Genetic studies 
have to be expanded to include other variants of the gene, the interaction with other genes, and possible epigenetic 
relationships.
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Background
The dopaminergic and opioid systems are part of a net-
work involved in rewarding response following the con-
sumption of opioids and other psychoactive substances 
[1, 2]. The dopamine system has been central to theo-
ries in reward of substance use disorder (SUD) that has 
been debated for several decades [3]. The consumption of 
addictive substances stimulates the release of dopamine 
into nucleus accumbens (NAc) elevating the dopamine 
level to above basal levels [4]. There are different mecha-
nisms of action and target molecules in the dopamine 
system for the variety of substances that are commonly 
consumed. This dopaminergic system comprises an array 
of dopamine receptors, transporters, and substance-
metabolising enzymes. Members of the family of the 
dopamine receptor genes, DRD1, DRD2, DRD3, DRD4, 
and DRD5, have been widely studied as risk factors for 
SUD [2]. The dopamine D2 receptor is a part of G pro-
tein-coupled receptors (GPCRs) that is encoded by the 
DRD2 gene. It is located on chromosome 11q23, span-
ning a region of 65.56 kilobases and comprises 8 exons 
separated by 7 introns. During the splicing process of the 
DRD2 mRNA precursor, two alternative subtypes of the 
D2 receptors are formed: a 443 amino acid D2L or a 414 
amino acid D2S form. The longer D2L form is more com-
mon [5]. This 29 amino acid difference between the two 
isoforms does not appear to affect the pharmacological 
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properties of the dopamine D2 receptor. The D2L/S vari-
ation changes the localization of the third intracellular 
loop of the receptor that interacts with the G coupled 
protein; hence, it affects the intracellular signalling mech-
anism. The mechanisms of dopamine receptor signal 
transduction and regulation are not only mediated via G 
protein signalling, but also involve G protein independ-
ent signalling events [6].
Understanding the reward and the treatment responses 
highlight the necessity of reviewing the relation between 
the genetic variants of these dopaminergic genes and 
SUD [7]. Patriquin et  al. [7] reviewed the correlation of 
dopaminergic genes to SUD. The genetic variants of 
DRD2 have been a focus of intense research to deter-
mine their link to SUD. Two single-nucleotide polymor-
phisms (SNPs) of the DRD2 loci; rs2283265 in intron 5 
and rs1076560 in intron 6 have been reported to be asso-
ciated with cocaine use [8]. A DRD2 variant (rs1076560) 
has also been studied in various populations. Clark 
et  al. [9] reported the association between rs1076560 
and opioid use in African Americans (AA) (p = 0.03) 
and European Americans (EA) (p = 0.02). These find-
ings introduced insights into the possible roles of these 
dopaminergic variants on SUD. However, the extent of 
genetic variations acting as a risk factor for SUD is still 
not understood.
The opioid receptor gene family has been extensively 
studied to identify if there are any associations with 
SUD. There three subtypes are μ, κ, and δ, encoded by 
the OPRM1, OPRK1, and OPRD1 genes, respectively. 
The product of the OPRM1 gene plays a role in facili-
tating the analgesia and euphoria effects of opioids. The 
G protein-coupled mu opioid receptor encoded by the 
OPRM1 gene is a multiple trans-membrane protein that 
has a high affinity for endogenous and exogenous opioids 
[10]. The OPRM1 gene consists of 9 exons which encode 
over 100 variants that produce between 19 and 39 splice 
forms of the protein [11]. The rs1799971 (A118G) site is 
an SNP that is located in exon 1 of the OPRM1 gene. This 
variant encodes a missense change in OPRM1 at posi-
tion 40 resulting in a change from an asparagine to an 
aspartate (Asn40Asp) in the extracellular domain of the 
receptor. This substitution eliminates an N-glycosylation 
site in the extracellular domain, which affects endog-
enous opioid binding and receptor activity [12]. The role 
of the rs1799971 in SUD remains in dispute [13, 14]. The 
effect of the variants of rs1799971 on different classes 
of substance has been extensively studied in various 
populations [10, 11, 13, 15–20]. However, only two stud-
ies [21, 22] have looked into rs1799971 variants in the 
Arab population. Several studies have reported associa-
tions between A118G with different substances of use in 
patients from different ethnic groups [10, 11, 13, 15–20], 
with others not finding significant associations with SUD 
[23, 24].
This study is the first study to report on the allele 
frequency for the rs1076560 SNP of DRD2 and the 
rs1799971 SNP of OPRM1 in individuals with SUD from 
the United Arab Emirates (UAE). This case–control study 
investigated the genetic association between the DRD2 
rs1076560 SNP and OPRM1 rs1799971 SNP and SUD 
in the UAE population. The allele frequencies of DRD2 
rs1076560 SNP in the UAE population were compared 
to other global populations. The allele frequencies of the 
OPRM1 rs1799971 SNP in this UAE study were com-
pared with SUD cohorts in other Arab populations.
Methods
Subject information
A total of 250 male nationals of the UAE were recruited 
from the National Rehabilitation Center (NRC) based 
on the nation’s capital of Abu Dhabi. All participants 
were previously diagnosed with SUD based on the 
DSM-5 criteria. Saliva samples were collected from each 
patient who had agreed to participate in this study, using 
the DNA Oragene saliva kit (DNA Genotek, Ottawa, 
Ontario, Canada). In addition, 262 male nationals of the 
UAE with no prior history of SUD or mental illness were 
recruited as controls. These individuals were part of an 
ongoing population study towards the establishment of 
the Emirates Family Registry (EFR) [25]. The characteris-
tics of the cohort are summarised in Alblooshi et al. [26] 
which includes socio-demographic data as well as the 
combination and types of substances that were used. The 
study was conducted in accordance with standards set 
by the World Medical Association of Helsinki [27]. Spe-
cifically, approval to study human subjects was obtained 
from the NRC in Abu Dhabi. In addition, reciprocal 
approval was obtained from the human ethic committee 
at the University of Western Australia (RA/4/1/6715).
Genotyping of single‑nucleotide polymorphism (SNP)
Genomic DNA was isolated from the cells in human 
saliva samples using the laboratory protocol for man-
ual extraction of DNA as recommended by Genoteck 
(Ottawa, Ontario, Canada). SNP genotyping was pre-
formed using a  TaqMan® SNP genotyping assay on the 
viiA™7 (Applied Biosystems Inc. (ABI); Foster City, CA, 
USA). For quality control (QC) purposes, 10% of sam-
ples that were studied were randomly selected. These QC 
samples were genotyped at least twice. There was 100% 
concordance between the genotypes recorded for repli-
cates from the same individual. The Hardy–Weinberg 
equilibrium (HWE) was calculated for both the cases 
and controls. No significant deviation from HWE was 
observed.
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Identification and inclusion criteria of relevant studies 
for comparison purposes
Life science journal articles containing information 
related to genotyping studies of the two SNPs of interest: 
DRD2 rs1076560 and OPRM1 rs1799971 were retrieved 
from a search of electronic publication databases. Spe-
cifically, articles in PubMed/MEDLINE (US National 
Library of Medicine), EMBASE (Elsevier B.V., Amster-
dam, The Netherlands), and ISI Web of Science (Thom-
son Reuters, New York, NY, USA) that were published 
to 15 March 2017 were retrieved. The search process 
was set up to specifically identify case–control studies 
that examined associations between each SNP (DRD2 
rs1076560 and OPRM1 rs1799971) with different types of 
SUD in different populations or ethnic groups. Data that 
were specifically extracted from these published studies 
for comparison included: (1) the number of cases and 
controls; (2) the ethnicity of the study population; (3) 
the genotyping method used; (4) allele and genotype fre-
quency data; (5) information related to Hardy–Weinberg 
equilibrium; and (6) the significance of the levels of asso-
ciations identified (p values and statistical tests).
Statistical analysis
Allele and genotype frequencies in the cases and controls 
from this study were calculated using the GenAlex pack-
age (Peakall and Smouse 2006, 2012) and association was 
determined using the STATA statistical software (College 
Station, TX, USA).
Results
The allele frequencies of the DRD2 rs1076560 SNP in the 
patient and control groups were compared. The Minor 
Allele Frequency (MAF) for DRD2 rs1076560 was the 
“A” allele, with a frequency of 11.80% in the substance 
use group compared with 13.20% in the controls. Corre-
spondingly, the “C” allele was 88.20% in cases and 86.80% 
in controls (Table  1). The χ2 allelic association between 
the DRD2 rs1076560 SNP and substance use was not sig-
nificant in the UAE population that was studied [p = 0.52, 
odds ratio (OR) = 0.88].
The results of this UAE study were compared with pub-
lished data that included association studies between the 
DRD2 rs1076560 SNP and the use of different substances 
(e.g., alcohol, cocaine, opioids, and poly-substances) in a 
number of different populations (e.g., Caucasians, Afri-
can Americans, Asians, and Jordanian Arabs) (Table  1). 
Six relevant publications matched the selection criteria 
described in the “Methods” section. All the studies iden-
tified were case versus control studies. Clark et  al. [9] 
studied a relatively large population of EA and AA (999 
EA cases versus 656 EA controls and 278 AA cases versus 
750 AA controls) and showed that the DRD2 rs1076560 
SNP was significantly associated with opioid use in both 
Table 1 Summary of the meta-analysis of the DRD2 rs1076560 in association with SUD in different populations
CI confidence intervals, OR odds ratio
** p value of Armitage test using the status of mixed opioids (n = 250) versus no addiction (n = 262)
a Mixed: include single substance and poly-substance users
Population Substance Phenotype Number Allele’s frequency 
(%)
p OR (95% CI) References
C A
Caucasians Alcohol Case 171 79.00 21.00 0.14 1.34 (0.90–1.98) [30]
Control 160 83.00 17.00
African Americans Opioid Case 278 88.00 12.00 0.03 1.43 (1.04–1.97) [9]
Control 750 91.00 9.00
European Americans Case 999 83.00 17.00 0.02 1.27 (1.04–1.54)
Control 656 86.00 14.00
African Americans Cocaine Case 45 94.00 6.00 0.53 0.66 (0.18–2.40) [27]
Control 31 92.00 8.00
Caucasians Case 74 76.00 24.00 0.003 2.74 (1.38–5.45)
Control 63 90.00 10.00
Japanese Alcohol Case 297 59.90 40.10 0.03 1.30 (1.02–1.66) [29]
Control 425 66.00 34.00
Jordanian Arabs Poly-substance Case 220 84.30 15.70 0.03 1.53 (0.90–2.68) [30]
Control 240 89.20 10.80
UAE Cohort Mixeda Case 250 88.20 11.80 0.52** 0.88 (0.61–1.28) This study
Control 262 86.80 13.20
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populations with p values of 0.02 and 0.03, respectively. 
The MAF of the DRD2 rs1076560 SNP was higher in EA 
case group (17.0%) when compared to EA control group 
(14.0%) as well as in AA cases (12.0%) versus AA con-
trols (9.0%) [9]. Moyer et  al. [28] studied cocaine users 
in the same two ethnic groups (EA and AA) and showed 
that the DRD2 rs1076560 SNP was associated with 
cocaine use in EA (p = 0.003, OR = 2.74), but not in AA 
(p = 0.53, OR = 0.66). A polish study of European alcohol 
users reported results that were not significant (p = 0.14, 
OR = 1.34). In a study of Japanese patients, the risk allele 
“A” of the DRD2 rs1076560 SNP was associated with 
alcohol use (p = 0.03, OR = 1.30) [29]. To date, there has 
only been one other study of patients of Middle Eastern 
descent. Al-Eitan et  al. [30] found the DRD2 rs1076560 
SNP to be associated with poly-substance use in a Jorda-
nian Arab population (p = 0.03, OR = 1.53).
The OPRM1 rs1799971 SNP genotype frequencies 
studied in two case–control studies of SUD in popu-
lations of Arab descent are summarised in Table  2. 
In this study, the MAF “G allele” was 15.4% in cases 
and 18.9% in controls. Overall, the association of the 
OPRM1 rs1799971 SNP was not significant in the UAE 
patients with SUD (p = 0.12, OR = 0.78). In comparison 
with an Egyptian Arab population, no significant asso-
ciation was reported between the OPRM1 rs1799971 
SNP and Tramadol use (p = 0.54, OR = 0.73) with MAF 
“G allele” of 5.2% in cases and 7.0% in controls. Simple 
combinations in both populations indicate significant 
association between the MAF “G allele” with SUD 
(p = 0.04, OR = 0.73). This enhanced the odd ratio value 
with no heterogeneity observed. The combined data were 
adjusted using Cochran–Mantel–Haenszel test that was 
close to the UAE cohort.
The combined genotype frequencies for the DRD2 
rs1076560 SNP and OPRM1 rs1799971 SNP are summa-
rised in Table  3. There were no significant associations 
between the combined genotypes of both SNPs in cases 
(p = 0.88) and controls (p = 0.23). The combined geno-
type CC/AA was the highest in cases (55.6%) and controls 
(50.8%). This was followed by the combined genotype 
CC/AG with similar representation in cases (22.0%) and 
controls (22.9%). The combined genotype of the AC/GG 
was not observed in any individuals in the case group. 
Whereas, this combined genotype was observed in 1.2% 
of the control group. There were no cases or controls 
subjects with the combined genotype, AA/GG.
Discussion
In the UAE cohort represented in this study, there was 
no significant genetic association between the DRD2 
rs1076560 SNP (p = 0.52) and SUD. The MAF of the 
DRD2 rs1076560 SNP was higher in the controls (13.2%) 
when compared to the substance users (11.8%). This was 
similar to the observations made in an AA population 
studied by Moyer et al. [28], where the MAF in cocaine 
Table 2 Distribution of the allele frequency of rs1799971 among Arab population
CI confidence intervals, MAF minor allele frequency, OR odds ratio
* p value of Cochran–Armitage test using allelic model
** p-hetero: p value of heterogeneity of Breslow–Day of homogeneity test
a Cochran–Mantel–Haenszel test (CMH) is a test used in the analysis of stratified or matched categorical data
Cohort Case Control p* OR (95% CI) p-hetero**
AA AG GG Sum MAF (%) AA AG GG Sum MAF (%)
UAE 175 73 2 250 15.4 171 83 8 262 18.9 0.12 0.78 (0.56–1.08)
Egypt-Arabs 69 8 0 77 5.2 43 7 0 50 7.0 0.54 0.73 (0.26–2.07)
Simple combination 244 81 2 327 13.0 214 90 8 312 17.0 0.04 0.73 (0.51–0.99)
M-H  adjusteda 0.78 (0.57–1.06) 0.75
Table 3 DRD2 rs1075650 and OPRM1 rs1799971 genotype combination among case–control of this cohort
SNPs OPRM1 rs1799971 Genotype
Case p Control p
AA AG GG AA AG GG
DRD2 rs1076560 genotype
 CC 55.60 22.00 0.80 0.88 50.76 22.90 1.91 0.23
 AC 13.20 6.40 0.00 12.60 8.78 1.15
 AA 1.20 0.80 0.00 1.91 0.00 0.00
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users (6.0%) was lower than in the control group at 
8.0%. In general, Moyer et  al. [28] reported an associa-
tion between the DRD2 rs1076560 SNP and cocaine use, 
in EA but not the AA. The overall odds ratio of 1.94 in 
population (n = 214) was attributed to an artefact aris-
ing from the small sample size that was studied [9]. In a 
more recent study, Clark et  al. [9] replicated the Moyer 
et  al. [28] study by increasing sample size. The DRD2 
rs1076560 SNP was found to be associated with opioid 
use disorder in the two populations examined in this 
subsequent study (EA: p =  0.02, AA: p =  0.03), but not 
cocaine use (EA: p = 0.23, AA: p =  0.19). The MAF of 
the DRD2 rs1076560 SNP, the “A allele”, was found to be 
higher in the cases when compared to controls in both 
populations: EA at 17.0% versus 14.0%, respectively, and 
in AA at 12.0% versus 9.0%, respectively [9].
The different association outcomes between the stud-
ies may account for the differences in the substance of 
use or the pattern of use in the cohorts that were studied. 
Table 1 summarises the type of substances in each study, 
which included alcohol, opioid, cocaine, and poly-sub-
stance use. Stratifying these studies based on the type or 
pattern of substance used is important to identify more 
specific genetic risk variants [31]. Iacono et al. [32] sug-
gested that specific substances influenced the nature of 
the genes that are involved in the pharmacodynamics and 
pharmacokinetics of that substance [31, 32]. However, it 
is a challenge to stratify patients according to substance 
of use, as often there is no single substance that is used by 
patients and there are overlaps between the substances 
are used. Clark et al. [9] investigated associations with a 
single substance. However, their study was plagued with 
difficulties related to overlap between different types of 
the used substances [9]. In addition, the differences in 
the genetic architecture between populations could dic-
tate whether a variant is associated or not (Table 1). For 
example, the association between DRD2 rs1076560 SNP 
and alcohol use was statistically significant (p = 0.03, 
OR = 1.30) in a Japanese population [29]. However, the 
same SNP was not statistically significant in the Polish 
patients with alcohol use disorder (p = 0.14, OR = 1.30) 
[33]. Even though the findings of Malecka et al. [33] were 
not significant, the MAF “A allele” in the group of alcohol 
users was higher in the cases (21.0%) than in the controls 
(17.0%). In contrast, the MAF “A allele” in this UAE study 
and the AA group in Moyer et  al. [28] were opposite, 
where the MAF “A allele” was higher in controls than in 
cases (Table 1).
This study found no significant genetic association 
between the OPRM1 rs1799971 SNP (p = 0.12) with SUD 
among patients from the UAE population. The asso-
ciation between the OPRM1 rs1799971 SNP and vari-
ous phenotypes of SUD has been studied and includes 
being a risk factor to different types of substances of 
use including tobacco consumption [34], alcohol use 
and sensitivity [13, 19, 34, 35], and opioid use [16, 36]. 
Other studies looked into inducing clinical symptoms 
or mediating responses to therapeutic treatment [11, 17, 
37, 38]. The association between the OPRM1 rs1799971 
SNP and SUD failed to reach statistical significance in 
our study (p =  0.12) and in a previous study by Enabah 
et al. [22] (p = 0.54). In addition, the MAF of the OPRM1 
rs1799971 SNP or “G allele” in our study (case = 15.4%, 
control = 18.9%) was distributed in a similar pattern to 
Enabah et  al. [22] (case = 5.2%, control = 7.0%), where 
the MAF “G allele” was lower in cases than in the con-
trols. However, by combining the two cohorts, as shown 
in Table 3, the increase in numbers resulted in a signifi-
cant association between the OPRM1 rs1799971 SNP 
and substance use. This suggests that a larger population 
size in future studies is required. The OPRM1 rs1799971 
SNP association varies and appears to depend on the 
study population and the nature of the substance of use. 
For example, Chen et  al. [35] examined the association 
between the OPRM1 rs1799971 SNP and alcohol use dis-
order in two different populations (Asian and Caucasian) 
in a meta-analysis study. They reported an association 
with the OPRM1 rs1799971 SNP in Asians (p ≤ 0.001) but 
not in Caucasian (p = 0.76). Other studies have reported 
a lack of association with alcohol use [24] and with 
heroin and/or cocaine use [16, 23]. Since the OPRM1 
rs1799971 SNP has been widely studied in different 
populations, we focused on compiling data based on the 
Arab studies (Table  2). Another Arab study by Al-Eitan 
et al. [21] investigated the role of OPRM1 variants includ-
ing the rs1799971 SNP on the outcomes of therapeutic 
treatment for opioids. This association between OPRM1 
rs1799971 SNP and the possibility of an increased chance 
of relapse in patients undergoing Naltrexone treatment 
for opioid use disorder in Jordanian patients was not sig-
nificant (p = 0.55). The variability of the findings from the 
range of studies conducted to date highlights some con-
tribution by the OPRM1 rs1799971 SNP. However, the 
variability in associations found to date requires further 
study to understand the contribution of this SNP.
This study is the first to examine if there is any associa-
tion between combined genotypes of two genes (DRD2 
rs1076560 SNP and OPRM1 rs1799971 SNP) and the sus-
ceptibility to SUD in patients of Arabian ancestry. There 
was no significant association found between the com-
bined genotype frequencies of the two SNPs and disease 
in this case–control study (cases p = 0.88 and controls 
p = 0.23). Although some studies support the combined 
effect of variants of these two genes (DRD2 and OPRM1), 
the exact mechanism remains elusive. This may suggest 
the involvement of other genetic variants within or in the 
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vicinity of the DRD2 and OPRM1 genes. For example, 
Zhang et al. [10] examined 13 SNPs in the OPRM1 gene 
using haplotype analysis in an association study involving 
substance use patients from two populations: European 
and Russian ancestries [10]. They reported the involve-
ment of the intronic variants of OPRM1 (rs511435, 
rs534731, rs3823010, rs2075572, and rs609148) in 
increasing risk to SUD. Some of these SNPs were located 
in linkage disequilibrium (LD) with OPRM1 rs1799971 
SNP and others have been postulated to be involved in 
transcription regulation or alternative gene splicing. The 
findings in Zhang et al. [10] highlighted the limitation of 
selecting a single SNP of a candidate gene to examine the 
genetic association with SUD.
Interaction between the DRD2 and OPRM1 genes with 
other genes has been examined across different sub-
stances of use. For instance, Lechner et al. [39] examined 
the combined effect of the OPRM1 rs1799971 SNP and 
the DRD4 exon 3 VNTR variants on cigarette craving 
after alcohol consumption. The study reported that the 
presence of the G allele is associated with an increase in 
cigarette craving after alcohol consumption. However, no 
significant association between to the exon 3 VNTR vari-
ants of the DRD4 were found with the condition [39]. In 
addition, Sullivan et al. [40] reported a gene–gene inter-
action between the dopamine receptors gene (DRD2) and 
the dopamine transporter gene (DAT) in cocaine users. 
The interaction between the regulatory variant of DRD2 
(rs2283265) and dopamine transporters gene altered 
DAT protein activity, supporting the possibility that vari-
ants being a risk factors for cocaine use [40].
Conclusion
This study provides insights into two major genes that are 
thought to be risk factors of substance use. Specifically, 
the DRD2 rs1076560 SNP and the OPRM1 rs1799971 
SNP were studied in substance use patients from the 
UAE population. No significant association between 
the DRD2 rs1076560 SNP, the OPRM1 rs1799971 SNP, 
and the combined genotype of the two SNPs and SUD 
was identified in this cohort. Nevertheless, future stud-
ies must consider stratification of the disease phenotype 
to assess possible association with DRD2 and OPRM1. 
In addition, the findings of this study might suggest the 
involvement of other variants or genes in the mecha-
nism of the disorder. Haplotype analyses for DRD2 and 
OPRM1 variants can be considered in future studies to 
evaluate the interaction of variants on each gene. Alter-
natively, genome-wide association study (GWAS) could 
be more objective strategy, since it does not rely on any 
previous conclusions from other populations.
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